Please assess the completion status of the following clinical trial:

Trial Title: PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed diagnosis of Hodgkin's lymphoma~2. Stage~   * Clinical Stage IA, IB, IIA with at least one of the risk factors a-d given below~  * Clinical Stage IIB with one or both risk factors c-d given below risk factors:~     * Large mediastinal mass (≥ 1/3 of the greatest thorax diameter as measured by chest x-ray)~    * Extranodal involvement~    * High erythrocyte sedimentation rate (≥ 50 mm/h in patients without B-symptoms, ≥ 30 mm/h in patients with B-symptoms)~    * Three or more involved lymph node areas~3. No prior therapy for Hodgkin's lymphoma (exception: pre-phase treatment with corticosteroids and vinca-alkaloids for a maximum of seven days may not preclude trial participation if clinically indicated and all staging examinations have been performed; all forms of prior radiotherapy preclude trial participation)~4. Age: 18-60 years~5. Signed informed consent with understanding of the study procedures and the investigational nature of the study~6. Patient agrees that personal data and tissue samples are provided to the GHSG (protection of privacy as defined by law will be ensured)~7. Life expectancy \> 3 months according to investigator judgement.~Exclusion Criteria:~1. Incomplete diagnosis of stage of disease~2. Prior or concurrent disease which prevents treatment according to protocol In particular the following contraindications:~   * Chronic obstructive pulmonary disease with global insufficiency~  * Symptomatic coronary heart disease~  * Cardiomyopathy or cardiac insufficiency (NYHA value of EF \< 50% or FS \< 25%)~  * Serious uncontrolled hypertension~  * Uncontrollable infection~  * Leucocyte concentration \< 3.000/mm3 or thrombocyte concentration \< 100.000/mm3~  * Creatinin clearance \< 60 ml/min~  * Bilirubin \> 2 mg/dl or GPT \> 100 U/l or GOT \> 100 U/I (exception: elevated values of Hodgkin's disease liver involvement)~  * HIV-Infection according to HIV test~  * Chronic or acute Hepatitis~3. HD as composite lymphoma~4. Prior chemotherapy or radiation~5. Malignant disease within the last 5 years (exceptions: basalioma, carcinoma in situ of the cervix uteri, completely resected melanoma TNMpT1)~6. Pregnancy, lactation, positive pregnancy test~7. Refusal to use effective contraception~8. WHO performance index \> 2~9. Long-term ingestion of corticosteroids (e.g. for chronic polyarthritis) or antineoplastic drugs (e.g. methotrexate)~10. Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the trial and to formulate his/her own wishes correspondingly~11. Non compliance: Refusal of blood products during treatment, epilepsy, drug dependency, change of residence abroad, prior cerebral injury or similar circumstances which appear to make protocol treatment or long-term follow-up impossible~12. Antiepileptic treatment~13. General intolerance of any protocol medication~14. Any contraindication for study medication according to the summaries of product information~15. Simultaneous participation in another clinical~16. Institutionalization by law~17. Relation of dependence with the sponsor's representative / trialist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).